Wilbur S M, Bonavida B
J Exp Med. 1981 Mar 1;153(3):501-13. doi: 10.1084/jem.153.3.501.
SJL/J (H-2 (8)) lymphocytes, primed in vitro against primary, cultured, and transplantable syngeneic reticulum cell sarcomas (RCS) were found to recognize and bind to the tumor without subsequent cytolysis. Additional data showed that the recognition was also directed against Ia molecules of the H-2(d), but not H-2(k), haplotype. Normal spleen cells of DBA/2, B 10.D2, and B 10.OL mice were bound, whereas those of CBA, B 10.BR, B 10.A, B 10.GD, and D2.GD were not. Furthermore, the Ia molecules were in the form of a hybrid, because spleen cells from F(1) progeny of a B10.A and a B10.GD parent were recognized and bound as effectively as the RCS. Recognition was not restricted solely to the H-2(d) haplotype. Spleen cells from B10.S(9R) mice were also significantly bound. This result suggested that the RCS expresses a hybrid Ia molecule containing a beta-chain of the H-2(8) haplotype. Recognition of this hybrid Ia molecule by the host resulted in a cross- reactive recognition of H-2(d) specificities. Further analysis revealed that the RCS express on their cell surface an alpha-chain of the hybrid Ia molecule which is involved in host anti-tumor recognition. Preincubation of the RCS with monoclonal antibody directed against the Ia.7 specificity on the alpha-chain could block lymphocyte-to-tumor cell binding. The blocking activity could be removed by preabsorption of the antibody on the RCS, as well as normal Ia.7-bearing lymphocytes, but not on lymphocytes that do not express Ia.7, such as SJL/J. The data suggest that the hybrid Ia molecules expressed on the RCS, and recognized by tumor-primed syngeneic lymphocytes, are composed of both a syngeneic and an alien chain. The component alien to the SJL/J host is the Ia.7-bearing alpha-chain. Normal SJL/J cells synthesize but do not express the beta-chain. In the RCS, however, alien alpha-chain synthesis permits expression of the syngeneic beta-chain in the form of a hybrid Ia molecule.
体外致敏的SJL/J(H-2(8))淋巴细胞,针对原发性、培养的和可移植的同基因网状细胞肉瘤(RCS),被发现能识别并结合肿瘤,但随后不会发生细胞溶解。其他数据表明,这种识别也针对H-2(d)单倍型的Ia分子,而不是H-2(k)单倍型。DBA/2、B10.D2和B10.OL小鼠的正常脾细胞会被结合,而CBA、B10.BR、B10.A、B10.GD和D2.GD小鼠的脾细胞则不会。此外,Ia分子呈杂交形式,因为来自B10.A和B10.GD亲本的F(1)后代的脾细胞与RCS一样能被有效识别和结合。识别并不局限于H-2(d)单倍型。来自B10.S(9R)小鼠的脾细胞也能被显著结合。这一结果表明,RCS表达一种含有H-2(8)单倍型β链的杂交Ia分子。宿主对这种杂交Ia分子的识别导致对H-2(d)特异性的交叉反应识别。进一步分析表明,RCS在其细胞表面表达杂交Ia分子的α链,该α链参与宿主抗肿瘤识别。用针对α链上Ia.7特异性的单克隆抗体对RCS进行预孵育,可阻断淋巴细胞与肿瘤细胞的结合。通过在RCS以及正常表达Ia.7的淋巴细胞上预吸收抗体,可去除阻断活性,但在不表达Ia.7的淋巴细胞(如SJL/J)上则不能。数据表明,RCS上表达的、被肿瘤致敏的同基因淋巴细胞识别的杂交Ia分子,由一条同基因链和一条异源链组成。对于SJL/J宿主而言,异源成分是携带Ia.7的α链。正常的SJL/J细胞合成但不表达β链。然而,在RCS中,异源α链的合成使得同基因β链以杂交Ia分子的形式得以表达。